Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Upamostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 19/20 | 0.97 |
| ▸ | PLG | P00747 | 15/20 | 0.81 |
| ▸ | F10 | P00742 | 7/20 | 0.81 |
| ▸ | F2 | P00734 | 6/20 | 0.81 |
| ▸ | ST14 | Q9Y5Y6 | 6/20 | 0.81 |
| ▸ | PLAT | P00750 | 4/20 | 0.81 |
| ▸ | HPN | P05981 | 2/20 | 0.81 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.81 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.81 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Upamostat SCHEMBL30343420 | 1.00 | PLAU (0.97) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL30085342 | 1.00 | PLAU (0.97) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL23548880 | 0.99 | PLAU (0.96) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL29376462 | 0.98 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL31331918 | 0.98 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL20669283 | 0.98 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL437037 | 0.98 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| SCHEMBL437042 | 0.93 | PLAU (0.90) | PLAUPLGF10F2ST14 | |
| Sulfuric Acid SCHEMBL23548435 | 0.91 | PLAU (0.80) | PLAUPLGF10F2ST14 | |
| Sulfuric Acid SCHEMBL23548437 | 0.91 | PLAU (0.80) | PLAUPLGF10F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117695284-A | Treatment of coronavirus infection | 红山生物医药有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11918560-B2 | Serine protease inhibitor for treating coronavirus infection | REDHILL BIOPHARMA LTD. (IL) | 2024-03-05 | — | — | US | disclosed |
| CN-115515560-B | Treatment of coronavirus infection | 红山生物医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4117630-A1 | TREATMENT OF CORONAVIRUS INFECTION | RedHill Biopharma Ltd. (IL) | 2023-01-18 | — | — | EP | disclosed |
| US-20210299108-A1 | SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2021-09-30 | — | — | US | disclosed |
| WO-2021181157-A1 | TREATMENT OF CORONAVIRUS INFECTION | REDHILL BIOPHARMA LTD. (IL) | 2021-09-16 | — | — | WO | disclosed |
| US-11045453-B1 | Serine protease inhibitor for treating coronavirus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045453-B1 | Serine protease inhibitor for treating coronavirus infection | PRSS1, ACE, TMPRSS2 | PLAU 67/4885PLG 95/4885F10 718/4885 |
| US-11918560-B2 | Serine protease inhibitor for treating coronavirus infection | PRSS1, ACE, TMPRSS2 | PLAU 67/4885PLG 95/4885F10 718/4885 |
| US-20210299108-A1 | SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION | PRSS1, ACE, TMPRSS2 | PLAU 67/4885PLG 95/4885F10 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.